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Abstract 23 
Glucocorticoids (GCs) are effective for the treatment of many chronic conditions but their 24 
use is associated with frequent and wide-ranging adverse effects including osteoporosis and 25 
growth retardation. The mechanisms that underlie the undesirable effects of GCs on skeletal 26 
development are unclear and there is no proven effective treatment to combat them. An in-27 
vivo model that investigates the development and progression of GC-induced changes in bone 28 
is, therefore, important and a well characterized pre-clinical model is vital for the evaluation 29 
of new interventions. Currently, there is no established animal model to investigate GC 30 
effects on skeletal development and there are pros and cons to consider with the different 31 
protocols used to induce osteoporosis and growth retardation. This review will summarize the 32 
literature and highlight the models and techniques employed in experimental studies to date.   33 
 34 
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Introduction and background  48 
It is estimated that, at any one time, over 250,000 people are exposed to systemic 49 
glucocorticoids (GCs); approximately 10% of children will require GCs at some stage 50 
during their childhood (Mushtaq & Ahmed 2002) and 5% of the population aged 80 years 51 
or over have used GCs in the past (Kanis et al. 2004). Long-term GCs are effective in 52 
many conditions, such as inflammatory bowel disease (Pappa et al. 2011), chronic renal 53 
disorders (Olgaard et al. 1992), lung conditions, hematological malignancies( El-Hajj 54 
Fuleihan et al. 2012) and connective tissue disease, and in some, such as Duchenne 55 
muscular dystrophy (DMD) (Matthews et al. 2016), they are the mainstay of long-term 56 
treatment.  Unfortunately, GCs are associated with frequent and wide-ranging side-effects, 57 
many of which are dose-related and associated with considerable morbidity. Of these, two 58 
of the potentially most serious and challenging to manage are glucocorticoid-induced 59 
osteoporosis (GIO) and growth retardation. Osteoporosis is characterized by a reduction in 60 
bone mass and loss of bone microarchitecture, leading to impaired bone strength and 61 
increased fracture risk (Reinwald & Burr 2008). GIO is the most prevalent type of 62 
secondary osteoporosis and accounts for about 25% of cases (Eastell et al. 1998). It is 63 
associated with considerable morbidity and mortality; a reduction in bone mineral density 64 
(BMD) of up to 40% can occur with GC therapy and it is estimated that up to half of those 65 
on long-term GC therapy will experience fractures (Reid 1997). In those with DMD, 75% 66 
are predicted to have a vertebral fracture after 8 years of GC therapy( Bothwell et al. 67 
2003) and this event is often followed by loss of ambulation (McDonald et al. 2002). The 68 
General Practice Research Database has shown that daily prednisolone doses of as little as 69 
2.5mg can cause an increased risk of fracture (Van Staa et al. 2000). A recent meta-70 
analysis also showed that there is only weak evidence for the use of common osteoporosis 71 
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drugs in the prevention of fractures (Amiche et al. 2016), suggesting that there is great 72 
need for preclinical work to inform the development of new therapies.  73 
 74 
As healthy children have high rates of bone growth, their skeleton is particularly 75 
vulnerable to the adverse effects of GCs on bone formation. GC-induced growth 76 
retardation was first described 60 years ago after an equivalent cortisone dose of only 77 
1.5mg/kg/day (Blodgett et al. 1956) and can be considerable; by 15 years of age, boys 78 
with DMD who are treated with deflazacort are 21 cm shorter on average than untreated 79 
boys (Biggar et al. 2006). GC-induced growth retardation can also occur following GC 80 
exposure by several alternative routes including inhaled GC in asthma (Allen et al. 1994) 81 
and intra-articular GC injections in juvenile arthritis (Umlawska & Prusek-Dudkiewicz 82 
2010). GC-induced growth retardation is dose-dependent and alternate-day or weekend 83 
dosing is associated with less growth retardation (Escolar et al. 2011; Ricotti et al. 2013). 84 
In children, although compensatory catch up growth may occur after cessation of GC 85 
therapy(Crofton et al. 1998), prolonged exposure may reduce the potential for catch up 86 
(Simon et al. 2002). 87 
 88 
Skeletal Development  89 
The fetal skeleton develops in two distinct ways; intramembranous ossification occurs within 90 
flat bones including the skull and facial bones, whereas endochondral ossification accounts 91 
for the linear development of the long bones such as the femur and tibia. Appositional growth 92 
also occurs, whereby bone lining the medullary cavity is reabsorbed and new bone tissue is 93 
laid down beneath the periosteum, thus increasing bone diameter.  This can still occur even 94 
after longitudinal growth ceases. In this review we shall focus on endochondral ossification, 95 
which is driven by the actions of the chondrocytes within the epiphyseal growth plate and is 96 
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the process responsible for bone formation and longitudinal growth of the majority of the 97 
skeleton. During the initial, patterning phase of skeletal development, mesenchymal cells 98 
condense into tissue elements at specific sites that form the structure of future bones 99 
(Karsenty & Wagner 2002). By 5 weeks gestation in humans, these pre-cartilaginous anlagen 100 
reflect the shape, size, position and number of skeletal elements that will be present in the 101 
mature skeleton (Javaid & Cooper 2002). Following this, differentiation to either 102 
chondrocytes or osteoblasts occurs within the condensations. Chondrocytes within each 103 
element organize into growth plates and move through their associated orderly pattern of 104 
resting, proliferative and hypertrophic phases (Mackie et al. 2011). Once they reach the 105 
hypertrophic phase, chondrocytes promote invasion of blood vessels and the production of an 106 
extracellular matrix (ECM) that is rich in type II collagen, aggrecan, cytokines and vascular 107 
growth factors which facilitates vascular invasion and gradual mineralization of the ECM 108 
surrounding the hypertrophic chondrocyte.  The cartilaginous ECM is gradually replaced by a 109 
bony ECM (rich in type I collagen), when apoptosis of the hypertrophic chondrocytes occurs 110 
and osteoblasts invade the cartilaginous scaffold. As osteoblasts lay down new bone, to form 111 
the periosteum, the primary ossification centre expands towards the ends of the cartilage 112 
model. In long bones, a secondary ossification centre subsequently forms at each end of the 113 
bone, leaving a cartilaginous growth plate in between the two ossification centres.  Growth is 114 
orchestrated at the growth plates but at puberty, bony bridges form between the ossification 115 
centers, resulting in the cessation of growth due to the fusion of the growth plate and its 116 
replacement by bone.  After birth, a continuing cycle of modelling (or remodelling in adults 117 
when it occurs without a change in bone shape) occurs and there is a fine balance between 118 
bone formation and bone resorption to ensure that bone can sense and adapt to alterations in 119 
functional, metabolic and mechanical demands.  120 
 121 
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 122 
GCs and their mechanisms  123 
Figure 1   124 
 125 
a) GC-induced osteoporosis 126 
The aetiology of GC-induced osteoporosis is complex and a detailed review of the underlying 127 
mechanisms as recently reported (Henneicke et al. 2014) is beyond the scope of the current 128 
review. Instead we will summarise the key mechanisms and the differing effects of GCs in 129 
osteoblasts, osteoclasts and osteocytes. There are two distinct phases of GC-induced bone 130 
loss, resulting from the suppressive effects of GCs on both osteoblastogenesis and 131 
osteoclastogenesis. The initial acute period of increased bone resorption is followed by a 132 
more indolent phase of bone loss caused by a reduction in bone formation (Canalis et al. 133 
2004).  Indirect effects of GCs on the skeleton such as decreased calcium absorption, 134 
increased renal calcium clearance, reduced growth hormone (GH) secretion and suppression 135 
of sex steroid metabolism were previously thought to play a fundamental role, but the main 136 
mechanisms underlying GIO are now known to result from the direct effect of GCs on the 137 
resident bone cells, see figure 1.  138 
Glucocorticoids and mineralocorticoids act through corticosteroid receptors - the 139 
mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR). These receptors have 140 
often been referred to as Type 1 and Type 2 corticosteroid receptors, respectively(Eberwine 141 
1999; Stewart 2007). The GR is expressed in many bone cells, including osteoblasts, 142 
osteoclasts and osteocytes (Bouvard et al. 2009) and also in chondrocytes within the growth 143 
plate.  Once GCs bind to the GR in the cytoplasm, the GR translocates to the nucleus, where 144 
it acts as a transcription factor and modifies gene expression, via the GC-response element, 145 
either by causing transactivation or transrepression. Transactivation accounts for most of the 146 
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GC-associated adverse effects and in-vitro and murine studies demonstrate that selective GR 147 
modulators can alter the extent of these adverse effects (Owen et al. 2007; Thiele et al. 2012). 148 
However, studies using transgenic mice with a GR gene mutation that prevents dimerization 149 
and therefore transactivation still have reduced bone formation. This suggests that 150 
transrepression is probably also at least partly responsible (Rauch et al. 2010). Polymorphism 151 
of the GR gene is associated with varying susceptibility to GCs (Huizenga et al. 1998) which 152 
may in part explain the heterogeneity in GC-associated fracture rates in humans.  153 
Micro RNAs (MiRNAs) are endogenous RNAs made up of 18-25 nucleotides that interact 154 
with messenger RNA to change protein expression. Recent work has shown that several 155 
MiRNAs have differential expression in GC-treated bone. For example, a reduction in 156 
MiRNA-29a expression, which interacts with Wnt signalling components and Dkk-1 during 157 
osteoblast differentiation was associated with GC-associated bone loss. Gain of MiRNA-29a 158 
function by a MiRNA-29a precursor (Wang et al. 2013) attenuated the deleterious effects of 159 
GC treatment on bone mass, microarchitecture, and biomechanical strength.  160 
 161 
Effects of GC on osteoblasts 162 
The chronic bone loss in GIO predominantly results from the ability of GCs to decrease 163 
both the number and functionality of osteoblasts. Osteoblasts and adipocytes are both 164 
derived from mesenchymal stem cells. By changing the fate of osteoprogenitor cells, GCs 165 
effectively reduce the pool of cells that can become mature, differentiated osteoblasts and 166 
bone marrow stromal cells are instead directed along the adipogenesis pathway. This has 167 
been shown to occur via the transactivation of CCAAT/enhancer binding protein in 168 
murine stromal cells(Pereira et al. 2002), which increases expression of peroxisome 169 
proliferator-activated receptor gamma 2 (PPARγ2) and suppresses expression of Runx2 170 
(Canalis et al. 2004, 2007). GCs may, therefore, increase bone marrow adipose tissue at 171 
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the expense of mature osteoblasts and cancellous bone (Weinstein & Manolagas 2000). 172 
Outside of bone, GCs also promote preadipocycte conversion to mature adipocytes and 173 
thus cause hyperplasia of adipose tissue. A 2-fold increase in cancellous adipocyte area in 174 
GC-treated mice compared to placebo has been reported, alongside a significant increase 175 
in adipocyte production in bone marrow cultures (Weinstein & Manolagas 2000). The 176 
exact mechanism(s) by which the reduction in osteoblastogenesis occurs is unclear, 177 
however, it is known that GCs cause suppression of bone anabolic factors such as bone 178 
morphogenetic proteins (Pereira et al. 2002), osteoblast-specific factor 2 (OSF-2) and 179 
insulin-like growth factor 1 (IGF-1) (Jones & Clemmons 1995) and TGF-β which activate 180 
osteoblastic transcription factors such as Runx2 and β-catenin. In cultured human 181 
osteoblasts, exogenous GC administration also results in suppression of the canonical 182 
Wnt-β-Catenin signaling pathway which prevents osteoblast apoptosis and encourages 183 
progression through the osteoblast cell cycle and thus proliferation (Ohnaka et al. 2005).  184 
Furthermore, murine GC exposure has been shown to upregulate sclerostin gene 185 
expression, which antagonises Wnt stimulation of osteoblast differentiation (Yao et al. 186 
2016). Using a transgenic mouse line, GCs have also been shown to suppress interleukin 187 
11 expression, which further inhibits osteoblast differentiation (Rauch et al. 2010). As 188 
well as inhibiting osteoblast differentiation, GCs also prevent bone matrix synthesis by 189 
inhibiting osteoblast-driven synthesis of type I collagen, which forms most of the ECM 190 
(Canalis 2005) and osteocalcin. GC administration to mice has also been shown to induce 191 
osteoblast apoptosis and suppress terminal differentiation (Weinstein et al. 1998).  192 
 193 
Effects of GC on osteoclasts and osteocytes 194 
Osteoclasts are derived from haematopoetic stem cells and resorb bone by creating an acidic 195 
environment and producing collagen-degrading enzymes. GCs exert an early direct effect on 196 
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osteoclasts by increasing both their number and activity, with a corresponding increase in 197 
bone resorption, seen after only 7 days of GC treatment in mice (Jia et al. 2006). This overall 198 
increase in osteoclast number occurs despite a reduction in osteoclast production in the bone 199 
marrow, suggesting that GC treatment increases the lifespan of pre-existing osteoclasts. 200 
However, the longer term role of the osteoclast in glucocorticoid-induced osteoporosis 201 
remains controversial; despite an initial increase in bone resorption, prolonged GC excess 202 
appears to suppress osteoclast number and function. For example,  after 4 weeks of 203 
prednisolone treatment in mice, bone resorption fell to or below normal levels (Weinstein et 204 
al. 1998). GCs also directly block the induction of cytoskeletal changes in the osteoclast 205 
required for the resorptive capabilities of the cell (Kim et al. 2007). There is also evidence 206 
that GCs suppress the proliferation of osteoclast precursors (Kim et al. 2006) However, GC 207 
also cause an increase in Receptor Activator of Nuclear Factor Kappa Beta Ligand (RANKL) 208 
(Hofbauer et al. 2009), which is produced by both osteoblasts and osteocytes (Nakashima et 209 
al. 2011; Xiong et al. 2011) and down-regulation of osteoprotegrin (OPG), which is a decoy 210 
receptor for RANKL. This skews the ratio of RANKL: OPG towards osteoclastogenesis. 211 
Overall, the long-term effect of exogenous GCs on osteoclastogenesis still requires 212 
clarification but it appears that the osteoblast is the main target of exogenous GCs. 213 
Osteocytes are terminally differentiated osteoblasts that play an important role in the repair of 214 
bone micro-damage. GCs alter the osteocyte-canalicular network by changing the elastic 215 
modulus surrounding the lacunae of osteocytes and cause reduced mineralisation (Lane et al. 216 
2006). Autophagy may be responsible for these observed localised osteocyte perilacunar 217 
changes, occurring as a self-protection mechanism during GC treatment  (Xia et al. 2010). 218 
High dose GC therapy in several animal and human models has also been shown to induce 219 
osteocyte apoptosis (Zalavras et al. 2003). 220 
 221 
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b) GC-induced growth retardation 222 
The growth-suppressing effects of GCs are multifactorial and result from both systemic and 223 
local actions on all types of bone cell. The GH/IGF-1 axis is the main determinant of 224 
postnatal longitudinal growth and GH and IGF-1 have interdependent roles in growth 225 
regulation. The rate of longitudinal bone growth is principally controlled through the 226 
regulation of chondrocyte proliferation, differentiation and hypertrophy at the growth plate 227 
(Wong et al. 2016). GH promotes chondrocyte differentiation, the secretion of IGF-1 by liver 228 
cells and the amplification of local IGF-1 synthesis by chondrocytes, which induces clonal 229 
expansion of chondrocyte columns within the growth plate (Zezulak & Green 1986).  230 
 231 
GCs also affect the expression of various components of the GH/IGF-1 axis (Price et al. 232 
1992; Jux et al. 1998; Klaus et al. 2000; Smink et al. 2002). Seven days of dexamethasone 233 
treatment in pre-pubertal mice reduced gene expression of IGF-1 throughout chondrocytes in 234 
all phases within the growth plate (Smink et al. 2003a) as well as causing a significant 235 
increase in the number of apoptotic cells within the hypertrophic zone. Different mechanisms 236 
of GC-induced apoptosis have been proposed such as activation of caspase 3 and suppression 237 
of Bcl-2 (Chrysis et al. 2003; Espina et al. 2008). GCs block the activation of GH and IGF-1 238 
receptors in chondrocytes as well as reducing IGF-1 and GH receptor expression by 239 
chondrocytes (Wong et al. 2016). Glucocorticoids also impair IGF-1 signaling, mainly via 240 
the phosphoinositide 3-kinase pathway within the growth plate. Furthermore, GCs suppress 241 
prostaglandin E2 synthesis (Harada et al. 1995) as well as vascular endothelial growth factor 242 
expression in chondrocytes, thus preventing blood vessel invasion of the ossification center, 243 
which is crucial for degradation of the ECM and subsequent ossification and growth (Smink 244 
et al. 2003a). The intrinsic effect of GC on the mouse growth plate was evident when a local 245 
dexamethasone infusion significantly reduced tibial growth compared to the contralateral 246 
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limb (Baron et al. 1992). GCs also act systemically to inhibit the pulsatile secretion of GH 247 
from the anterior pituitary gland by increasing somatostatin tone (Mazziotti & Giustina 248 
2013). 249 
 250 
Animal models of GIO and GC induced growth retardation  251 
It is essential to utilise animal models that show similar pathology to the human disease 252 
process that is under scrutiny, in order to effectively carry out pre-clinical studies and test 253 
novel compounds. GCs may lead to some localized changes in bone strength that are similar 254 
to other causes of osteoporosis, but they also display some unique effects which explains why 255 
GC exposure is associated with a higher risk of fracture at equivalent BMD and hence 256 
reinforcing the need for an appropriate animal model to specifically investigate GIO (Lane 257 
2005; Xia et al. 2010). In addition, the search continues to find selective GR agonists that 258 
possess the anti-inflammatory benefits of traditional GCs without the associated adverse 259 
effects (Sundahl et al. 2015). Suitable pre-clinical models are also vital to this process.  260 
It remains a challenge, however, to find an appropriate animal model for preclinical studies 261 
of skeletal development as there is no single animal model that exactly mimics the human 262 
pathology. Whilst larger animals such as primates and dogs may have the most similar 263 
reproductive, anatomical and physiological characteristics, there are ethical issues to consider 264 
as well as difficulties with their maintenance and costs (Reinwald & Burr 2008). Sheep, 265 
rabbits, and pigs have also been developed as large animal models of GIO in previous studies 266 
(Scholz-Ahrens et al. 2007; Baofeng et al. 2010; Ding et al. 2010) but these too have 267 
limitations. The following section will discuss the various animal models used to investigate 268 
both GIO and GC-induced growth retardation. 269 
Animal species used for GC-induced osteoporosis models 270 
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Different animal species have been used to explore the effect of GCs on the development of 271 
osteoporosis and to search for substances that prevent the observed deleterious effects. The 272 
inquiry performed on PubMed, with “osteoporosis”, “glucocorticoids” and “animal name” 273 
used as MeSH terms, retrieved 70 papers for rats, 34 for mice, 16 for rabbits, 11 for sheep, 5 274 
for pigs and 3 papers for zebrafish. Although the popularity of rats is related to their 275 
established position in postmenopausal osteoporosis research, as evidenced by FDA 276 
guidelines (Thompson et al. 1995), murine models are increasingly used nowadays. Mice are 277 
considered to be an appropriate pre-clinical model of GIO.  They share more than 95% of the 278 
human genome and can be readily genetically manipulated to simulate specific human 279 
diseases. It is also possible to control for the variability found in humans and undertake 280 
experiments that would otherwise be impossible in humans.  They also have the added 281 
advantage of being relatively easy and cost-effective to maintain. The adult mammalian 282 
skeleton undergoes a continuous remodeling cycle and some of the early pre-clinical studies 283 
using different species failed to appreciate this. More recent work has shown that the mouse 284 
shows a similar pattern to human GIO, with an early phase of osteoclast mediated bone 285 
resorption, followed by a more indolent phase of decreased osteoblastogenesis and bone 286 
formation (Yao et al. 2008). Unlike in humans, however, mice lack osteons (or the Haversian 287 
system) in cortical bone and therefore remodelling within this structure does not occur as it 288 
does in humans  (Jilka 2013). Marked effects on bone structural parameters caused by GCs 289 
are more frequently observed in younger animals, but in order to avoid complications in bone 290 
measurements due to loss of weight caused by GC, it has been suggested that skeletally 291 
mature animals should be used to investigate GIO. Gene knockout and transgenic approaches 292 
have also established the usefulness of the mouse in determining which genes are critical for 293 
bone turnover (Rauch et al. 2010). The mouse has also been used effectively in other models 294 
of bone loss, such as androgen or estrogen loss and ageing (Pogoda et al. 2005). However, 295 
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with regard to bone density and quality, dogs appear to be most similar to humans and rats 296 
the least (Aerssens et al. 1998). Interestingly, in vivo and in vitro bone mineral imaging as 297 
well as scale mineralization studies in zebrafish were described as a very simple alternative to 298 
explore alterations in mineralization pathways to GC challenge (Barrett et al. 2006). 299 
Techniques to measure GIO 300 
Osteoporosis is defined as an alteration of bone structure leading to increased fragility and 301 
fracture rate. In humans, clinically significant fractures and inappropriately low BMD serve 302 
as diagnostic criteria for osteoporosis. There is no such consensus on criteria defining 303 
osteoporosis in animal models. As spontaneous fractures do not occur in most animal models, 304 
unlike in humans, suitable proxy outcome measures need to be utilized. The following 305 
methods have been used to describe changes in bone health after GC exposure: 306 
 307 
Bone histomorphometry 308 
Traditional methods to assess changes in bone structure include the evaluation of histological 309 
sections of mineralized bone. In basic osteoporosis research, lumbar vertebral bodies and 310 
long-bone (typically, femoral and tibial) metaphyses are examined to investigate trabecular 311 
(cancellous) bone changes, whereas cortical bone alterations are assessed within the 312 
diaphysis of long-bones. In addition to the primary static measures, so-called dynamic 313 
parameters can also be calculated using the primary measures assessed on bone histological 314 
sections after appropriate fluorochrome labeling.  315 
 316 
Dual-energy x-ray absorptiometry 317 
Dual-energy x-ray absorptiometry (DXA) is widely used for BMD evaluation in the clinical 318 
as well as research setting. DXA assesses areal BMD (aBMD = bone mineral content/bone 319 
area). The precision of in vivo DXA scans has been shown to be very good in mice 320 
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(coefficients of variation < 2 %) at total body (excluding head), lumbar spine (L4-L5), whole 321 
femur and whole tibia sites (Iida-Klein et al. 2003). This enables longitudinal BMD 322 
observations to be used in murine osteoporosis studies. However, in studies, DXA scans have 323 
often been performed on different skeletal sites ex vivo as an outcome measure (see Table 1). 324 
The main drawback of DXA is that there is no information on bone structure or quality. Bone 325 
mass increases with body mass, therefore, smaller and younger animals will have lower BMD 326 
compared to larger and older ones, but not necessarily more fragile bones. Since experimental 327 
drugs, such as GCs, may affect body weight or growth (as discussed later), size should be 328 
taken into account to prevent the introduction of bias regarding the effect on BMD. However, 329 
bone size adjustments are rarely undertaken in murine osteoporosis studies (none of the 330 
studies listed in Table 1).  331 
 332 
Peripheral quantitative computerized tomography and Micro-computerized tomography 333 
By using peripheral quantitative computerized tomography (pQCT), true volumetric BMD 334 
can be assessed, that, together with bone architecture and geometry, allows for calculation of 335 
bone strength and structural indices. These indices correlate very well with whole bone 336 
strength when tested ex vivo (Siu et al. 2003; Kokoroghiannis et al. 2009). Micro-337 
computerized tomography (µCT) is normally used at a resolution of 1-10µm in rodents 338 
(Bouxsein et al. 2010). Major advantages compared to 2D histological sections are the 3D 339 
nature of the data, so that real mineralized bone matrix volumes in whole bone tissue 340 
volumes (BV/TV) can be assessed, faster data acquisition and larger bone region under 341 
investigation.  342 
 343 
Biomechanical testing and biochemical markers of bone metabolism 344 
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Although the primary aim may be focused at the molecular, cellular, tissue or whole bone 345 
organ level, the crucial clinically relevant outcome of the numerous papers focusing on 346 
osteoporosis research is to increase bone strength and reduce fracture risk. Bone tissue is a 347 
complex and metabolically active structure and, at the organ level, bone continuously adapts 348 
to mechanical loading and other environmental factors to mitigate the stress and sustain its 349 
function. Therefore, none of the above mentioned parameters alone can sufficiently mirror 350 
actual bone health. Biomechanical testing is the only method capable of verifying whether a 351 
treatment may cause or prevent bone fragility. In laboratory animals, bone competence is 352 
usually tested through axial compression of the vertebral bodies or three-point bending of 353 
long bones (Jepsen et al. 2015). 354 
Distinct biochemical markers in serum/plasma are also used to follow disease or drug-355 
mediated changes in bone formation (Glendenning 2011). 356 
 357 
GC type and dose to induce osteoporosis 358 
Prednisolone (or prednisone), methylprednisolone and dexamethasone are the most frequent 359 
synthetic GC used in osteoporosis animal models (see Table 1). However, they have distinct 360 
differences in potency. Although the following order from the most to least potent is in 361 
agreement with several studies (i.e., dexamethasone > methylprednisolone > 362 
prednisolone/prednisone > hydrocortisone/corticosterone), the relative efficacy may vary 363 
based on the assay or method of evaluation (Meikle & Tyler 1977; Tanaka et al. 1994; 364 
Buttgereit et al. 2002). The relative efficacy and potency of GC may also depend on the 365 
system studied, for example the potency for effects on bone metabolism may be quite 366 
different to those on glucose and fat metabolism (Ahmed et al. 2002; Wallace et al. 2003). In 367 
addition, it is not yet clear whether genomic or non-genomic pathways play the major role in 368 
GIO (Hartmann et al. 2016). Altered bone structure was observed in two-month-old male 369 
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mice treated with 15 mg/kg/day of corticosterone (Herrmann et al. 2009), but only 2.8 370 
mg/kg/day of methylprednisolone was needed to induce similar changes in mice of same age 371 
and sex (Yao et al. 2016). Therefore, methylprednisolone appears to be more potent than 372 
corticosterone in osteoporosis induction. Another study showed decreases in bone density, 373 
bone formation rate and bone strength in 6-month-old C57BL/6 male mice treated with 374 
prednisolone 2.1 mg/kg/day over 28 days, but the same dose was not sufficient to induce 375 
significant changes in female mice (Weinstein et al. 2011). By contrast, the same 376 
prednisolone dose was used in female mice of similar age, but different strain (i.e., Swiss 377 
Webster), and significant decreases were observed in bone density, bone formation and bone 378 
strength after only 10 days (Plotkin et al. 2011). This highlights that sex- as well as strain-379 
specific efficacy may be present with different GCs. Controlling for sex (male), strain (Swiss 380 
Webster) and route of administration (slow release subcutaneous pellets), 3-month-old mice 381 
required 5.6 mg/kg/day of prednisolone, the highest dose tested, to induce a significant 382 
decrease in mineralizing surface/ bone surface (MS/BS) and bone strength (Jia et al. 2011) 383 
whereas a decrease in MS/BS and BMD was observed in 7-month-old mice challenged with 384 
2.1 mg/kg/day of prednisolone (Weinstein et al. 1998). Therefore, mouse age and pubertal 385 
status may be an additional factor influencing the potency of the tested GCs. In humans a 386 
dose of dexamethasone of 1mg is equivalent to 6mg of prednisolone, therefore consideration 387 
of the dose used relative to clinical application is important.  388 
It is also important when investigating GIO to describe the impact on both trabecular and 389 
cortical bone as there are discrepancies between data obtained at different sites, see table 1. 390 
 391 
Route of administration in GIO models 392 
Osteoporosis is induced by systemic administration of GC. Many studies implemented 393 
regular intramuscular, intraperitoneal or subcutaneous injections, but single implantation of 394 
Page 16 of 54
 17
slow release subcutaneous pellet or oral gavage have also been used (see table 1). In rats of 395 
the same strain and age, daily oral gavage of GCs over a 90 day period (Lin et al. 2014) led 396 
to similar adverse effects on bone (as assessed by histomorphometry and aBMD) as thrice 397 
weekly subcutaneous injections of GC over 56 days (Iwamoto et al. 2008). By contrast, a 398 
much shorter period of intervention is necessary to induce osteoporosis with daily injections 399 
(Ogoshi et al. 2008) or continuous infusion through subcutaneously implanted osmotic 400 
pumps (King et al. 1996). Daily injections are stressful for the animals, which may negatively 401 
influence the outcome and ethical regulations in some countries may not allow multiple 402 
repeated injections over a long time period. For example, the injection of carrier alone (PEG 403 
400) caused a 3-fold increase in serum corticosterone levels in mice, compared to a 5-10 fold 404 
increase induced by an intraperitoneal injection of 10 mg corticosterone/kg body weight, 1 405 
hour after injection (Herrmann et al. 2009). This technique of administration would also not 406 
be acceptable to most patients in the clinical trial setting. Micro-osmotic pumps were found 407 
to have a large variation in residual volumes 21 days after implantation. With a ﬁlling volume 408 
of 250 µL, residual volumes containing active drug ranged from 50 to 180 uL, which 409 
indicated major differences in the ﬂow-rate of individual pumps (Herrmann et al. 2009). 410 
Subcutaneous insertion of slow release pellets containing corticosterone leads to more 411 
consistent drug levels as compared to subcutaneous injections of corticosterone. Oral gavage 412 
seems to be less effective compared to daily injections or slow release subcutaneous pellets, 413 
but has the most translational relevance, as this would be the most accepted method of GC 414 
administration in the clinical setting. Whilst slow release pellet insertion may reduce 415 
unnecessary repetition of periodical injections over the study period their safety and efficacy 416 
needs further validation. 417 
 418 
Animal models of GC-induced growth retardation 419 
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It is likely that different animal models are required to investigate GIO and growth 420 
retardation. Poor choice of model may result in misinterpretation of results and limited 421 
translational promise. For example, the young growing rat does not show any bone loss or 422 
changes in microarchitecture of trabecular bone and modelling is the prevailing activity,  423 
therefore it is a poor model for human GIO (until at least 9 months of age when the transition 424 
to remodelling occurs). It does appear, however, to be a good model to mimic the growth 425 
retardation seen in children exposed to GC (Lelovas et al. 2008). For growth studies, the age 426 
and status of sexual maturity at the time of growth plate closure must also be considered. 427 
Unlike humans, bone acquisition and longitudinal bone growth continue in mice and rats 428 
after sexual maturity. Linear bone growth in rodents increases during the largest proportion 429 
of life expectancy in comparison with other species (Kilborn et al. 2002). Humans and 430 
primates (showing the second highest ratios of age at growth plate closure to life expectancy), 431 
cows and sheep are also considered adults at the age when growth plate closure occurs. By 432 
contrast, rabbits, dogs, and cats would be described as very young adults at the time of physis 433 
closure. In mice, whilst the highest growth phase is from weaning until sexual maturation, 434 
body weight continues to increase in the mouse up to the end of the 52nd week and long bone 435 
growth continues slowly after puberty (Jilka 2013).  By contrast, New Zealand white rabbits 436 
begin sexual maturation at approximately 2 months of age and undergo epiphyseal fusion by 437 
approximately 6 months of age. Therefore in order to induce growth retardation and allow for 438 
subsequent catch-up growth in one study, GC challenge was commenced when the rabbits 439 
were 5 weeks of age (Weise et al. 2001). Nevertheless, using rabbits at a young age proved 440 
problematic for Kugelberg and colleagues who were unable to sex them at 3 weeks of age 441 
and therefore had to use both males and females in their study (Kugelberg et al. 2005). This 442 
is important as imprinting (Jansson et al. 1985) by androgen secretion of the neonatal rodent 443 
Page 18 of 54
 19
brain has been shown to result in sex differentiation of body growth and, therefore, it is also 444 
important to consider which sex of animal is most relevant to the research question.  445 
 446 
Techniques to assess bone growth rate 447 
When studying mammalian growth, simple gross parameters such as weight, body or tail 448 
length have historically been used as proxies for growth rates (Hughes & Tanner 1970), and are 449 
still routinely recorded when assessing growth in pre-clinical studies. These measurements 450 
can be very inaccurate however, and dependent on other confounding factors (Melin et al.). X-451 
ray determination of the length of different long bones with the aid of anatomical landmarks 452 
(Weber et al. 1968) is a simple but more accurate proxy.  Recent advances in imaging also 453 
mean that tibial/femoral length can be accurately measured using micro (µ)CT. This is often 454 
performed in conjunction with other measures of trabecular and cortical bone structure 455 
(Waarsing et al. 2004; Bouxsein et al. 2010). In addition, in vivo µCT is a non-invasive 456 
imaging technique that allows longitudinal bone growth to be evaluated over a period of 457 
weeks or months in the same animals and would therefore be well suited for monitoring GC-458 
induced growth retardation. This can be a cost effective and ethical method as it reduces the 459 
number of animals required for a study and also minimizes intra-subject variability. Potential 460 
drawbacks include the dose of ionizing radiation delivered through multiple scans and the 461 
potential for radiation associated tissue effects on the growing skeleton (Klinck et al. 2008; 462 
Laperre et al. 2011). Inclusion of a non-irradiated contralateral limb would clarify the 463 
magnitude of this potential issue.  Also, by administering fluorescent labels (Owen et al. 464 
2009) at known time intervals, the bone formation rate (BFR) at the chondro-osseous 465 
junction can be assessed visually under UV light, without the need for further staining or 466 
decalcification (Dobie et al. 2015).  In addition to the methods used to assess the growth rate 467 
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of the entire bone, measures of the tibial epiphyseal growth plate width have been used for 468 
over 50 years as a reliable proxy indicator of growth rate (Interlichia et al. 2010).  469 
More recently, a number of investigators have used ex vivo models such as rodent metatarsals 470 
in culture (Mårtensson et al. 2004; Mushtaq et al. 2004). For example, when fetal mouse 471 
metatarsals were cultured for up to 10 days with either daily or alternate day dexamethasone 472 
at 10-6M, dexamethasone treated bones paralleled control bone growth rate until day 8 when 473 
their rate of growth decreased resulting in a total length that was significantly reduced from 474 
controls at days 8 and 10 (Mushtaq et al. 2004). 475 
  476 
It is well established that the rate of linear bone growth is dependent on growth plate 477 
chondrocyte proliferation, matrix turnover and changes in chondrocyte shape and size 478 
(Hunziker & Schenk 1989; Farquharson & Jefferies 2000). Advances in quantitative 479 
histology now enable the growth plate to be scrutinized in greater detail to assess the 480 
contribution of the different chondrocyte activities to overall growth rate.  Whilst quantitative 481 
histology techniques were developed in the 1970’s to assess the relationship between cell 482 
division in growth cartilage and overall bone growth, chondrocyte proliferation is now 483 
routinely quantified by the immunohistochemical detection of BrdU incorporation into 484 
proliferating cells in tissue sections of the growth plate (Farquharson & Loveridge 1990).  485 
Cell death of hypertrophic chondrocytes within the growth plate is also required for 486 
physiological bone growth and the TUNEL assay allows the detection and quantification of 487 
apoptotic cells within a population of chondrocytes (Kyrylkova et al. 2012).  488 
 489 
GC type and dose to induce growth retardation 490 
The inquiry was performed on PubMed, with “growth retardation” or “growth”, 491 
“glucocorticoids” and “animal name” used as MeSH terms. When summarising the data, we 492 
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have not included studies where only gross body measurement parameters were taken as a 493 
subset of a larger study. Studies where only an abstract was available were also excluded. 494 
Where the same groups have published multiple work using the same species and 495 
methodology, only the initial data has been represented in table 2.  496 
As shown in Table 2, dexamethasone was the most frequently used GC in the growth 497 
retardation models that we reviewed. Method of administration and dosage varied greatly, 498 
consistent with the GIO models. Rodents were used in the majority of studies. Four of the 499 
studies administered subcutaneous injections of dexamethasone to mice of between 3 and 5 500 
weeks of age. All used daily injections, except for one, where a 5-times weekly regimen was 501 
followed (Rooman et al. 1999). The length of course varied from 7 to 28 days and the dose 502 
used varied from approximately 0.02mg/kg/day to 5mg/kg/day. In one of the studies, where 503 
three varying doses were used, the lowest dose of 0.2µg (approximately 0.02mg/kg/day) did 504 
not cause significant growth reduction, but both the 2µg and 20µg doses caused similar 505 
growth retardation (Rooman et al. 1999). No differing side-effects were reported in the two 506 
groups. When a dose of 2mg/kg/day was used, body weight was reduced only in males and 507 
femur length only in females, whilst a significant reduction in body weight was demonstrated 508 
by day 3 using 5mg/kg/day in females in a different study (Owen et al. 2009). It would, 509 
therefore, appear that there is a sex difference in response to GCs and that an optimal dose 510 
would be greater than 2mg/kg/day to ensure significant growth retardation in both sexes. 511 
However, the rapid catabolic response with a reduction in body weight by day 3 seen with a 512 
dose of 5mg/kg/day would suggest the need for close monitoring (Owen et al. 2009).  513 
 514 
We reviewed 8 studies using rats, usually either Wistar or Sprague-Dawley and up to 4 515 
months of age at study induction. All except two studies used only male rats. Length of 516 
course varied greatly from 4 to 90 days. In one of the studies using prednisolone, 517 
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10mg/kg/day was originally chosen (after a previous study by the same authors demonstrated 518 
no effect on cortical bone using 5mg/kg/day (Ortoft et al. 1992)) but after observing 519 
unexpectedly high weight loss, the dose was decreased to 5mg/kg/day. Using 5mg/kg/day 520 
they were able to demonstrate reduced longitudinal bone growth of the lumbar vertebrae. 521 
This highlights one of the problems of using body weight as a reflection of growth. GC can 522 
show a dual metabolic effect on body weight, depending on the dosage, method of 523 
administration and length of treatment. High dosages can cause a catabolic effect and loss in 524 
body weight whereas lower dosages can cause an increase in appetite and associated weight 525 
gain (as frequently seen in humans). For example, 1mg/kg single dose of dexamethasone 526 
given to piglets caused accelerated growth at 18 days of age (Carroll 2001). Piglets are also 527 
noted to have a metabolic response to GCs that closely mimics the response observed in 528 
infants and children receiving long-term GC therapy (Ward et al. 1998). One of the studies 529 
using Wistar rats demonstrated inhibition of growth after only 10 days of either inhaled 530 
budesonide or fluticasone (Kemer et al. 2015), even at a dose of only 50mcg. This is 531 
particularly relevant when considering that inhaled GCs are the treatment of choice for 532 
persistent asthma symptoms in both children and adults.  533 
 534 
 Decreased bone growth has been demonstrated even at concentrations as low as 1mg/kg/day 535 
in a study of rats, where doses of up to 9mg/kg/day of methylprednisolone were used (Ortoft 536 
et al. 1998a). In this study there was no discernible dose-specific side-effects although serum 537 
insulin levels were reduced in all groups.   These authors also noted that the catabolic effect 538 
of 9mg/kg/day of methylprednisolone (Ortoft et al. 1998b) by daily subcutaneous injection 539 
was less than that noted when a 5mg of depot prednisolone was used in rats of a similar age 540 
(Ortoft et al. 1998a). This suggests that routes of administration must also be considered.  541 
 542 
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Three studies were reviewed which used rabbits; each of these used dexamethasone, but via a 543 
different method of administration (eye drops, local infusion and daily subcutaneous 544 
injection) therefore they cannot be directly compared. However, all studies reported 545 
significant reductions in growth within the dexamethasone-treated groups. All rabbits were 546 
aged 5 weeks or less at study induction and all were aged 11 weeks or less at time of cull. In 547 
the only pre-clinical model to use a topical method of GC administration, significant effects 548 
on growth were demonstrated (Kugelberg et al. 2005).  549 
 550 
Three studies used piglets, all of whom were less than 7 weeks of age at the end of the study. 551 
Again a variety of routes of GC administration were used. It would appear that a dose of 0.25 552 
mg/kg/day of dexamethasone is insufficient to induce bone growth retardation in young 553 
piglets (Śliwa et al. 2005). In a similar study, a reduction in growth velocity persisted only 554 
when piglets were dosed with 0.3mg/kg/day and above (Ward et al. 1998) and when 555 
prednisolone, at an equivalent dexamethasone dose of 0.75mg/kg/day was used, a significant 556 
change in growth plate histology was seen (Smink et al. 2003b). 557 
 558 
It appears that higher equivalent doses of GCs are used in rodents compared to larger 559 
mammals such as rabbits and piglets.  In young mice, an optimal dose of dexamethasone 560 
when administered by daily subcutaneous injection seems to be between 2 and 5 mg/kg/day. 561 
This review demonstrates that there are a varied number of different methods that can be 562 
employed effectively to cause GC-induced growth retardation. However, unlike the review of 563 
GIO, we found no studies using implantable pellets or osmotic mini-pumps that measured 564 
growth parameters and therefore further studies are required to clarify their effectiveness of 565 
these delivery routes in causing growth retardation. Having highlighted the pitfalls of using 566 
the gross parameter body weight as a marker of growth; we propose that any future studies 567 
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should also use other confirmatory parameters of growth such as bone length measurements, 568 
BFR or growth plate histology.  569 
Genetically engineered animal models  570 
Global deletion of GR is lethal and mice die of respiratory failure due to lung atelectasis on 571 
the first day of life (Cole et al. 1995) therefore it is not possible to create a complete GR-572 
knockout model. However, tissue-specific genetically modified mouse models can be useful 573 
to tease out the effect of GCs on interlinked reactions between the different types of bone 574 
cells. For example, deleting osteoblast-specific GR conferred protection from GIO, while 575 
deleting osteoclast-derived GR had no effect (Rauch et al. 2010). Development of col 2.3 and 576 
col 3.6 hydroxysteroid dehydrogenase (HSD)2 transgenic mouse models that activate 11β-577 
HSD2 in osteoblasts showed decreased vertebral trabecular and femoral cortical bone mass, 578 
without any change in serum GC levels (Liu et al. 2004), thus implicating a role for 579 
endogenous GC signaling within the osteoblast for optimal bone mass acquisition.   580 
 581 
Conclusion  582 
In this review we have demonstrated that there are specific outcome measures that should be 583 
assessed when investigating either GIO or GC-induced growth retardation. We carried out a 584 
literature review with the aim of determining the most appropriate animal model to use when 585 
demonstrating the effects of GC on growth and bone structure, but results are too 586 
heterogeneous to enable one specific model to be advocated over another in all situations. 587 
However, there is sufficient evidence to recommend that investigation of GC-induced growth 588 
retardation in mice should be performed using dexamethasone 2-5 mg/kg/day by daily 589 
subcutaneous injection and the outcome measures should include serial lengths (using 590 
consistent measuring technique) and/or growth plate width and BFR; the measurement of 591 
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body weight for assessing linear growth is too inaccurate. When investigating GIO, there is 592 
insufficient evidence to recommend one specific mode of delivery over another but in most 593 
studies a dose of prednisolone 2-5mg/kg/day in mice has been sufficient. Recommended 594 
outcome measures include volumetric BMD (by pQCT or µCT rather than by DXA for 595 
greater accuracy) and bone biomechanical testing to mimic fracture rate in clinical studies.  596 
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Figure 1: systemic consequences of exogenous glucocorticoids and effects on different bone 
cells and adipocytes.  
Legend- RANKL; receptor activator of nuclear factor kappa-B ligand, OPG; osteoprotegrin, 
BMP2; bone morphogenetic protein 2, OSF-2; osteoblast-specific factor- 2, IGF-1; Insulin-
like growth factor-1,  TGF, transforming growth factor beta. 
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Table 1. Animal models of glucocorticoid-induced osteoporosis 
Species Sex + 
Age 
GC type, 
duration, 
administration, 
dose 
Body Weight 
(compared to 
baseline) 
Bone 
site 
Bone Imaging 
Technique 
Histomorphometry  
(GC vs Controls) 
µCT 
(GC vs control) 
DXA 
(GC vs 
control) 
Bone Strength Testing 
(GC vs control) 
Ref 
Mice, FVB F, 3 w Dex, 28 days 
working day SC 
14.3 ug/mouse/d 
NA  
 
Fem uCT NA BV/TV: no diff NA NA (Postnov et al. 
2009) 
Mice, ICR M, 6-8 w Dex, 28 days, 
daily IP inj., 2.5 
mg/kg/d 
No change in GC 
group, + 15 % in 
controls 
Tib Histomorph, (tib), 
pQCT (tib diaphysis) 
BV/TV - 45 % pQCT: no difference in 
vBMD, Cortical 
Thickness - 57 % 
NA NA (Du et al. 2011) 
Mice, mod 
Swiss 
Webster 
backgrnd 
M, 2 m Pred, 21 days, sc 
pellet, 0.8, 2.8 
and 4.0 mg/kg/d 
-20 % in GC 
groups, +24 % in 
controls 
Fem 
LS 
Histomorph,(L4, fem 
shaft); uCT (L5, 
distal fem) 
MS/BS - 50 %, BFR/BS - 65 % 
in highest GC group only 
BV/TV - 22 % in highest 
GC group only 
NA Axial compression (L6), 4-
point-bend test (fem) 
L6: Max Load -48 % and -61 % 
in 2 higher doses GC gps, resp; 
no diff  at fem 
(Yao et al. 2016) 
Mice, Swiss 
Webster 
M, 2 m Pred, 21 days, sc 
pellet, 3.3 
mg/kg/d 
- 20 % in GC 
group; + 25 % in 
controls 
Fem 
LS 
Histomorph (L4, 
L5,fem diaphysis); 
uCT (fem diaphysis, 
L5) 
L5: MS/BS -46 %, BFR/BS -60 
%; Fem: diaphyseal 
endocortex: BFR/BS -91 %, 
diaphyseal periosteum -92 % 
L5: BV/TV -32 %; distal 
fem: BV/TV: no diff 
NA Axial compression (L6), 3-
point-bend test (femur) 
Max Load: L6: -24 %, fem: no 
diff 
(Dai et al. 2015) 
Mice, WT 
littermates 
of 
transgenic 
offspring 
M, 8 w Cort, 28 days, sc 
pellet, NA 
NA Tib 
LS 
Histomorph(prox 
tibia); uCT (L3, tibia) 
Zero endocortical BFR/BS at 
tib 
L3: BV/TV: no diff; tibial 
metaphysis: BV/TV: no 
diff; tib diaphysis: 
Cortical thickness: no 
diff 
NA 3-point-bend test (tib) Max 
Load: no diff 
(Henneicke et al. 
2011) 
Mice, CD1 
Swiss 
White 
M, 7-9 w Cort, 28 days, sc 
pellet, 15 
mg/kg/d 
NA Tib 
LS 
uCT (L3, tibia) NA L3: BV/TV - 33 %; tibia: 
BV/TV - 56 % 
NA NA (Herrmann et al. 
2009) 
Mice, 
C57BL/6J + 
129/SvJ 
F+M,  
9 w 
Cort, 28 days 
sc pellet  
every week 
NA 
+ 27 % in GC 
groups; + 3 % in 
controls 
Tib QCT NA Trab BMD:-12% F,-21% 
M BV/TV -20% F,-27%M 
cort vBMD decreased, 
but not cort thickness/ 
bone area 
NA NA (Tamura et al. 
2015) 
Mice, 
C57BL/6 
F,  
8-10 w 
Dex, 17 days 
working day IP  
88 ug/mouse/d 
NA Fem pQCT NA Trab vBMD :+30%, 
Cort thickness: -9% 
 
NA NA (Grahnemo et al. 
2015) 
Mice, 
C57BL/6J 
F, 3 m Dex, 84 days 
thrice wk IM 
2.1 mg/kg/d 
NA (at end GC 
group +22 % v 
controls) 
Tib Histomorph,;CT NA BV/TV - 47 % NA NA (Cheng et al. 2015) 
Mice, Swiss 
Webster 
M, 3 m Pred, 28 days, sc 
pellet, 1.4, 2.8 
and 5.6 mg/kg/d 
NA F Histomorph MS/BS -40-60 % (in two 
highest GC doses) 
NA NA Axial compression (L6) (Jia et al. 2011) 
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Mice, 
C57BL/6 
F, 4 m Pred, 28 days  
sc pellet 
1.4, 2.1 mg/kg/d 
No change Fem 
LS 
Histomorph (LS)  
DXA (LS; fem) 
uCT (LS) 
MS/BS: no diff,  
BFR/BS: -36% 
BV/TV: no diff 
Cort thickness: -22% 
LS: 
aBMD: -
5% 
Fem: 
no diff 
Axial compression (LS) 
No diff  
(Sato et al. 2016) 
Mice, Swiss 
Webster 
M, 4 m Pred, 28 days, sc 
pellet, 2.1 
mg/kg/d 
NA LS Histomorph(L5);  
DXA (L? in vivo) 
BV/TV - 66 % NA aBMD change from 
baseline - 9 % in GC gp 
and - 4 % in controls,  
(sig diff between grps) 
NA (Li et al. 2016) 
Mice, Swiss 
Webster 
F, 5 m Pred, 10 days  
sc pellet 
2.1 mg/kg/d 
NA LS Histomorph, 
DXA  
BV/TV: -23%,  
MS/BS: -86%,  
BFR/BS: -90% 
NA aBMD: - 18% Axial 
compression 
(LS) 
Max Load: - 
34% 
(Plotkin et al. 
2011) 
Mice, Swiss 
Webster 
M, 5 m Pred, 28 days, sc 
pellet, 5.0 
mg/kg/d 
No change by 
end (-15 % after 
2 wks in GC gp) 
Tib Histomorph, ; uCT BV/TV -22 %, MS/BS -61 %, 
BFR/BS -75 % 
BV/TV no difference NA NA (Bouvard et al. 
2013) 
Mice, 
C57BL/6 
M, 6 m Pred, 56 days, sc 
pellet, 2.8 
mg/kg/d 
NA Fem 
LS 
uCT (L3, femoral 
diaphysis) 
NA L3: BV/TV - 25 %; 
femoral diaphysis: 
Cortical thickness -20 % 
NA NA (Fumoto et al. 
2014) 
Mice, 
C57BL/6 
M, 6 m Pred, 28 days, sc 
pellet, 2.1 
mg/kg/d 
NA LS Histomorph,(L1-L4); 
uCT (L5); DXA (L1-L4 
in vivo) 
BFR/BS - 49 % BV/TV not diff aBMD - 11 % Axial 
compression 
(L6) 
(Weinstein et al. 
2011) 
Mice, Swiss 
Webster 
M, 6 m Pred, 56 days, sc 
pellet, 5.0 
mg/kg/d 
NA Fem uCT NA BV/TV no difference (- 
30 % at day 28) 
NA NA (Yao et al. 2008) 
Mice, 
BALB/c 
F, 7 m Dex, 14 & 21 
days daily IP 
1.0, 5.0, 10 
mg/kg/d 
No change Fem 
Tib 
LS 
Histomorph (Fem, 
Tib, L5) 
uCT (Fem, Tib, LS) 
Fem: BV/TV: no diff, Fem: 
MS/BS: -62%, Fem: BFR/BS: -
74% (at mid GC dose) 
Fem BV/TV: + 11%; 
LS: no diff 
NA NA (McLaughlin et al. 
2002) 
Mice, Swiss 
Webster 
M, 6 m Pred, 21 days, sc 
pellet, 1.4 
mg/kg/d 
-10 % after 1 wk, 
regained initial 
weight by study 
end (no diff GC v 
control by end) 
LS Histomorph(L5); 
uCT (L5) 
BV/TV -19 %, MS/BS - 31 %, 
BFR/BS - 80 % 
BV/TV - 22 % NA Axial 
compression 
(L3) 
Max Load: no 
dif 
(Lane et al. 2005) 
Mice, Swiss 
Webster 
M, 7 m Pred, 27 days, sc 
pellet, 0.7 and 
2.1 mg/kg/d 
NA (tendency to 
lower weights in 
GC grps by end) 
Fem 
LS 
Histomorph(L?, 
femur), DXA (L? in 
vivo) 
BV/TV - 39 %, MS/BS - 26 %, 
BFR/BS - 53 % (in higher GC 
group only) 
NA aBMD change from base 
- 3,- 7,- 9 % in controls, 
lower, higher GC dose 
groups, respectively (sig 
diff between higher GC v 
control) 
NA (Weinstein et al. 
1998) 
Mice, Black 
Swiss + 
129SvJ 
M, 7 m Pred, 28 days 
sc pellet, 2.1 
mg/kg/d 
NA  
 
Fem 
LS 
Histomorph,(LS, 
Fem); pQCT (LS, 
Fem) 
LS: BV/TV: -31% 
LS: BFR/BS: 84% 
Fem: no difference 
pQCT: vBMD no diff NA Axial 
compression 
(LS);  
3-point bend 
test (femur) 
(Hofbauer et al. 
2009) 
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Max Load: LS: 
- 29 %, Fem: 
no diff 
Rabbits, 
Japanese 
white 
 
F, 6 m MP, 28 days, 
daily IM inj., 2.0 
mg/kg/d 
- 9 % in both 
control and GC 
groups 
Fem 
LS 
DXA (fem head and 
shaft), uCT (fem, L4) 
NA osteonecrosis after 8 
wks (4-wk treatment + 
4-wk wash out) in  fem 
head 
aBMD: femoral head - 
33 %; fem shaft - 22 % 
NA (Lin et al. 2016) 
Rabbits, 
New 
Zealand 
white 
F, 8 m MP, 56 days, 
daily IM inj., 1.0 
mg/kg/d 
No change LS DXA (L3-L4 in vivo), 
uCT (L3-4) 
NA BV/TV - 17 % aBMD - 25 % Axial 
compression 
(L3-4) Max 
Load - 19 %, 
no diff in 
Stiffness 
(Baofeng et al. 
2010) 
Rabbits, 
New 
Zealand 
white 
F, 8 m MP, 28 days, 
daily IM inj., 1.5 
mg/kg/d 
No change (no 
details were 
shown) 
LS 
Knee 
DXA (L3-L4, knee) NA NA aBMD: spine - 9 %; knee 
- 19 % 
NA (Castañeda et al. 
2008) 
Rabbits, 
New 
Zealand 
white 
M, 8 m Dex, 84 days, 
twice a week IM 
inj., 0.9 mg/kg/d 
Slight increase in 
all groups (no 
numbers shown) 
LS Histomorph (L3), 
DXA (L3-L4) 
BV/TV - 39 % NA aBMD - 27 % Axial 
compression 
(L4) Max Load 
- 38 %, 
Stiffness - 34 
% 
(Yongtao et al. 
2014) 
Rats, 
Wistar 
M, 2 m Pred, 42 days, 
oral gavage every 
second day, 15 
mg/kg/d 
NA Tib pQCT (tibial 
diaphysis) 
NA Cortical vBMD -2 %, 
Cortical thickness: no 
diff, SSI - 25 % 
NA NA (Yokote et al. 
2008) 
Rats, 
Sprague-
Dawley 
F, 3 m Dex, 84 days, 
twice a week IM 
inj., 0.7 mg/kg/d 
 
No change Multi 
sites 
DXA (head, upper 
limb, fem, trunk, rib, 
pelvis, spine, whole 
body) 
NA NA aBMD: spine - 18 % NA (Jiang et al. 2016) 
Rats, 
Sprague-
Dawley  
F, 3 m MP, 56 days, 
thrice a week SC 
inj., 2.1 mg/kg/d 
 
No change Tib 
Fem 
Histomorph,(tib  
diaphysis); DXA 
(fem) 
MS/BS - 60 %, BFR/BS - 76 % NA aBMD - 5 % NA (Iwamoto et al. 
2008) 
Rats, 
Sprague-
Dawley 
M, 3 m Pred, 90 days, 
daily oral gavage, 
1.5, 3.0 and 6.0 
mg/kg/d 
+33 % in GC 
groups; +62 % in 
controls 
Tib 
Fem 
LS 
Histomorph (fem, 
tibia); DXA (fem, 
L5); uCT (L6) 
tib: BV/TV: no diff, MS/BS - 
27 % (high GC-gp only), 
BFR/BS - 52 % (all 
combined); fem: BV/TV: no 
diff, MS/BS - 39 % (comb), 
BFR/BS - 38% (comb) 
BV/TV: no difference aBMD: fem: - 8 %; L5: no 
diff 
Axial 
compression 
(L5), 3-point-
bend test 
(fem) Max 
Load: fem: - 7 
% (no diff with  
lowest dose), 
L5: -22 %; 
Stiffness: fem: 
(Lin et al. 2014) 
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-17 % (no diff 
with lowest 
dose), L5: 
data not 
shown 
Rats, 
Wistar 
F, 3, 6, 
12 m 
Pred, 28 days, 
daily SC inj., 2.0 
and 20 mg/kg/d 
+ 9 %, + 3 % No 
change in 
controls; +5%, 
no change, -8 % 
in high GC group 
(3, 6, 12-mth old 
mice, resp.) 
Tib pQCT (tib 
metaphysis and 
diaphysis) 
NA Trab vBMD higher/ 
lower/not diff (3/6/12-
mth old), Cortical vBMD 
unchanged in either 
group (only %changes 
from baseline  given) 
NA NA (Ogoshi et al. 
2008) 
Rats, 
Sprague-
Dawley 
F, 6 m MP, 30 days, 
thrice a week SC 
inj, 3.0 mg/kg/d 
No change (no 
details shown) 
Tib 
Total 
Body 
Histomorph(tib)DXA 
(total body) 
BV/TV - 11 %, MS/BS - 13%, 
BFR/BS - 18 % 
NA aBMD - 8 % NA (Dalle Carbonare 
et al. 2007) 
Rats, 
Sprague-
Dawley 
F, 8 m MP, 60 days, 
daily SC inj, 30 
mg/kg/d 
NA Fem DXA NA NA aBMD - 9 % 3-point-bend 
test (femur) 
Max Load - 27 
% 
(Bitto et al. 2009) 
Rats, 
Wistar 
M, 8 m MP, 42 days, 
weekly SC inj, 1.0 
mg/kg/d 
NA Femur 
LS 
Histomorph (distal 
fem); DXA (L2-L4 in 
vivo) 
BV/TV -34 % NA aBMD -1% in controls,- 
10 % in GC  (sig diff 
between gps) 
NA (Wimalawansa & 
Simmons 1998) 
Rats, 
Sprague-
Dawley 
M, NA 
200-
225g 
Dex, 19 days, 
continuous pump 
infusion, 16.3 
ug/rat/d 
+ 8 % in GC 
group, + 52 % in 
controls 
Fem Histomorph BV/TV - 50 % NA NA NA (King et al. 1996) 
 
Abbreviations- aBMD: areal bone mineral density, BFR/BV: bone formation rate / bone surface, BV/TV: bone volume/tissue volume, Cort: corticosterone, 
Dex: dexamethasone, DXA: dual x-ray absorptiometry, F: female, Fem: femur, GC: glucocorticoid, Histomorph: histomorphometry, LS: lumbar spine, 
M: male, MAR: mineral apposition rate, MP: methylprednisolone, MS/BS: mineralizing surface / bone 
Surface, mths: months, NA: not available, Pred: prednisolone, pQCT: peripheral quantitative CT, QCT: quantitative CT, Tib: tibia, uCT: micro CT, vBMD: 
volumetric BMD, wks:weeeks 
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Table 2 Animal models of glucocorticoid-induced growth retardation 
Species Sex + age GC duration, method, dose Measurement Bone site Results Ref 
FVB Mice F, 3 wks Dex, 5 days a week for 4 wks, Daily 
SC inj, 0.2 µg, 2µg or 20µg/ animal/ 
day 
(approx. 0.02mg- 2mg /kg/day) 
 
BW, snout-tail length under anaesthesia 
weekly 
After cull, organs weighed, tib dissected, 
length measured using digital caliper. 
Tib dissected- GP width. 
tib Dex at 2 and 20µg/ day caused reduction in: 
- wt of tib, humerus and lumbar vertebra (only vertebra sig) 
- wt of organs esp. liver/muscle 
- total width of GP (mainly due to reduction in proliferative zone).   
Tibia length only slightly affected. No change in hypertrophic zone.  
(Rooman et al. 1999) 
FVB mice F, 3 wks Dex, 7 days, Daily SC inj, 20µg/day 
(approx. 2mg /kg/day) 
 
BW 
Nose-tail length 
Tibiae dissected- GP width and zones 
TUNEL assay 
tib Dex caused reduction in:- 
- total body weight (16.7 v 13.6g) 
- length gain (1.9 v 1.3cm) 
- tib GP width (dec in width of proliferative zone) 
- number of prolif chondrocytes 
 Inc in number of apoptotic chondrocytes. 
(Smink et al. 2003a) 
BL6 and BL6 (P21-/-
)mice 
F, 4 wks Dex, 7 days, Daily SC inj, 
5mg/kg/day 
Daily BW, nose-rump body length on days 1 
and 7. 
Digital caliper measurement of tib and organ 
weights after dissection.GP zone widths. 
Calcein labelling to measure MAR. 
tib Dex treatment caused reduction in:-  
- BW by D3 and CRL by D7 (8.2 v 7.6 cm)  
- liver, spleen and tibia Wt  
- GP width (esp in PZ and HZ)  
- MAR.  
(Owen et al. 2009) 
Homozygous Bax-
deficient and C57BL6 
mice 
Both, 30-
32 days 
Dex, 28 days, Daily SC inj, 2mg/kg Body weight 
Bones measured weekly by X-ray 
BrdU histology, TUNEL assay 
fem Dex caused reduction in: 
- fem growth (by 47% in female, 50% in males 
- BW (only significant in males) 
- chondrocyte proliferation and chondrocyte column density.   
Inc no. apoptotic chondrocytes. 
(Zaman et al. 2012) 
Wistar rats Both, 10 
days 
Budesonide 10 days, inhaled, 50 or 
200mcg 
 Fluticasone propionate 10 days, 
inhaled, 50 or 250mcg 
 
BW change during study period 
Tib dissected-GP zone widths, proliferation 
and apoptosis rates using Ki-67 and Tdt 
markers 
 Lowest weight gain in high dose fluticasone group 
All GP zone widths lower than controls (only significant at higher 
doses, more marked in high dose fluticasone than budesonide) 
Proliferative cell rates sig lower than controls 
Apoptosis in hypertophic zone of high dose fluticasone group almost 
doubled 
(Kemer et al. 2015) 
Sprague–Dawley rats M, 23 
days 
Dex, 24 days, Daily intra-peritoneal 
inj, 40 μg/kg /day. 
BW bi-weekly 
Nose-anal length prior to cull 
 Dex caused reduction in:  
- final BW (118 v 106g) 
- nose-anal length (18.5 v 17.8 cm) 
- growth rate (7.4 v 6.1g/day) 
(Tulipano et al. 2007) 
Long-Evans rats M, 37 
days  
Cortisone, 4 days, Daily SC inj, 1 
mg/25 g BW/ day 
BW, tail length 
Right tib measured after cull, with calipers.  
GP Width measured 
tib Cortisone treatment showed reduction in: 
- tail + tib length 
- BW velocity  
Wider epiphyseal GP width seen. 
(Mosier & Jansons 1989) 
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Sprague  Dawley rats M, 7 wks Dex, 7 days, Daily SC inj, 
5mg/kg/day 
BW 
Growth rate by calcein labelling of tibia. 
TUNEL assay 
tib Dex caused reduction in:  
- BW (23% loss v 32% gain in controls.  
- growth rate (68 /207µm day) 
- chondrocyte column density  
4-fold increase in apoptosis in THCs 
(Chrysis et al. 2003) 
Wistar rats F, 2 mths Methylpred, 90 days, Daily SC inj, 
Variable dose- 1,3,6 or 9 mg/kg/day 
BW weekly. Nose-tail length, length of R lower 
extremity weekly for 4 wks, then fortnightly 
using sliding caliper. Calcein/ tetracycline 
labelling of GP sections from prox tib after 
dissection. 
fem, tib Dose-dependent decrease in: 
- weight gain 
- nose-tail length 
- fem and tib lengths (even at 1mg/kg/day) 
- growth at the prox epiphyseal GP 
- muscle mass 
Effect seen after 1 wk, persisted for study duration. 
(Ortoft et al. 1998b) 
Sprague– Dawley rats  
 
M, 3 
mths 
Pred, 90 days, Oral gavage, Varied- 
1.5/3.0/6.0 mg/kg/day 
BW weekly 
Calcein/ tetracycline labelling to measure MAR 
and longitudinal growth rate  
fem, tib Pred caused dose dependent reduction in:- 
- BW (11.4, 14.7 and 19.2% with pred at 1.5/3.0/6.0 mg/kg/day 
respectively) 
- fem metaphyseal growth rate 
6.0mg/kg/day caused reduction in periosteal MAR of tib cortex.  
(Lin et al. 2014) 
Wistar rats M, 3 
mths 
Corticosterone, 3 wks, Daily SC inj, 
10mg/day (approx 40mg/kg/day) 
BW 
TUNEL assay 
Tib dissected- GP width. 
tib Corticosterone caused reduction in: 
- BW velocity 
- GP width  
Increased apoptosis of terminal hypertrophic chondrocytes. 
(Silvestrini et al. 2000) 
Wistar rats F,105 
days 
Pred, 80 days, Daily SC inj, 
5mg/kg/day (initially 10mg/kg/ 
day-  dec due to s/e) 
BW 
Height of L5 vertebrae 
LS Longitudinal bone growth of L5 arrested  (Ortoft et al. 1998a) 
New Zealand white 
rabbits 
Both, 3 
wks 
Dex, 8 wks, Eye drops, 20µl 10 
times daily over 13 hr period.  Gp 1- 
all doses, Group 2-alt doses. Ave 
daily dose 0.24 to 0.62 mg/kg/day. 
BW and crown-rump length weekly 
Fem length measured after cull by micrometer 
fem Dex caused dose-dependent reduction in: 
- crown-rump length 
- fem length  
- BW gain 
(Kugelberg et al. 2005) 
New Zealand white 
rabbits 
M, 4 wks Dex, Local infusion into one 
proximal tibial GP, over 7 days, 
80ng/µl, 1µl/hr 
Serial radiographs of pinned tibia tib Dex caused reduction in: 
- epiphyseal growth rate compared with contralateral side.  
Most marked at days 5-8. Recovered by day 21. 
(Baron et al. 1992) 
New Zealand white 
rabbits 
M, 5 wks Dex, 5 wks, Daily SC inj, 0.5 mg/kg 
per day  
 
Fem length measurement using digital caliper. 
Oxytetracycline labelling of longitudinal 
growth. Fem dissected- GP width/ zones. 
Chondrocyte prolif rate. 
fem Dex caused reduction in:  
- fem length  
- heights of the total GP, prolif and hypertrophic zones  
- BW gain  
(Weise et al. 2001) 
Large Polish White 
piglets 
Both, 2 
days 
Dex, 12 days, IM inj every 2nd day, 
0.5mg/kg of birthwt 
BW at start and end of study 
Length of fem, hum (technique not specified) 
fem, hum Dex treatment caused reduction in: 
- BW 
- Femoral and humerus bone length (not significant) 
(Śliwa et al. 2005) 
Yorkshire piglets M,4- 5 
days  
Dex, 15 days, bd by orogastric 
gavage, Tapering- 5 days each of 
0.5, 0.3 and 0.2 mg/kg/d 
Body weight, snout to rump length, fem 
length using single photon absorptiometry 
fem Dex caused reduction in: 
- length by day 6 and BW by day 11.  
Growth velocity reduction persisted only with 0.3 and 0.5mg/kg/day  
(Ward et al. 1998) 
Cross-bred piglets 
(Landrace x Yorkshire) 
F, 6 wks Pred, 5 days, oral, 5mg/kg/day Tib dissected- GP width. TUNEL assay tib Pred caused reduction in: 
- total GP widths to 81% of controls,proliferative zone 
- trab bone length  
7-fold inc in apoptotic chondrocytes in hypertrophic zone. 
(Smink et al. 2003b) 
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Abbreviations- BD: twice daily, BW: birthweight, Dex: dexamethasone, F: female, Fem: femur, GP: Growth plate 
 IM: intramuscular, Inj:injection, LS: lumbar spine, M: male, MAR: mineral apposition rate, mths: months, Pred: prednisolone, SC:SC, S/E:side-
effects, tib: tibia, Wks: weeks,  
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Bone formation 
Bone resorption 
Mesenchymal stem cell 
Adipocyte 
Osteoblast 
Osteoclast Osteocyte 
GC excess: 
Sex steroid production
↑ Calcium excretion
↓ Calcium absorption
– Secondary hyperparathyroidism
↑ Apoptosis
Altered elastic modulus
↓ Mineralisation
↑ RANKL
↓ OPG
↑ Apoptosis
↓ Differentiation
↓ Synthesis of type 1 collagen 
Suppression of BMP2, OSF-2, IGF-1, TGF-β
Down-regulation of Wnt-β catenin
↑ RANKL
↓ OPG
↑ Life span pre-exisitng osteoclasts
↓ Apoptosis of mature osteoclasts
↑ PPAR γ 2
↓ Runx2
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